6 minute read
Sep. 7, 2023

The First Isoform-Selective FGFR2 Inhibitor

lirafugratinib (RLY-4008)

oral covalent FGFR2 inhibitor Ph. II for cholangiocarcinoma from rational design with MD simulations Cancer Discov., June 4, 2023 Relay Therapeutics Inc., Cambridge MA

twitterlinkedinprintemail

MOTY Nominees

Molecule of the Year